Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Estradiol

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

33 API Suppliers, 11 USDMF, 12 CEP/COS, 2 JDMF, 3 EU WC, 10 KDMF, 34 NDC API, 4 VMF, 17 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

42 Drugs in Development

42 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

551 FDF Dossiers, 229 FDA Orange Book, 222 Europe, 29 Canada, 34 Australia, 27 South Africa, 10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.025MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.0375MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.06MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.075MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.1MG/24HR, INSERT, EXTENDED RELEASE;VAGINAL - 0.0075MG/24HR, SYSTEM;TRANSDERMAL - 0.025MG/24HR, SYSTEM;TRANSDERMAL - 0.0375MG/24HR, SYSTEM;TRANSDERMAL - 0.05MG/24HR, SYSTEM;TRANSDERMAL - 0.075MG/24HR, SYSTEM;TRANSDERMAL - 0.1MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.14MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.25MG/24HR, TABLET;ORAL - 0.5MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 1MG;0.5MG, TABLET;VAGINAL - 10MCG, TABLET;VAGINAL - 25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 0.5MG;100MG, CAPSULE;ORAL - 1MG;100MG, GEL, METERED;TRANSDERMAL - 0.06% (1.25GM/ACTIVATION), FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR, TABLET;ORAL - 0.25MG;0.5MG, TABLET;ORAL - 0.5MG;1MG, GEL, METERED;TRANSDERMAL - 0.06% (0.87GM/ACTIVATION), SPRAY;TRANSDERMAL - 1.53MG/SPRAY, GEL;TRANSDERMAL - 0.1% (0.25GM/PACKET), GEL;TRANSDERMAL - 0.1% (0.5GM/PACKET), GEL;TRANSDERMAL - 0.1% (0.75GM/PACKET), GEL;TRANSDERMAL - 0.1% (1.25GM/PACKET), GEL;TRANSDERMAL - 0.1% (1GM/PACKET), CREAM;VAGINAL - 0.01%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 8 SPI Pharma, 12 DKSH, 6 Faran Shimi Pharmaceutical, 6 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 33 BASF, 1 BioSpectra, 1 Clariant, 14 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 2 Lubrizol Life Science Health, 16 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 3 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 20 Roquette, 16 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 12 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

87 Fillers, Diluents & Binders, 60 Coating Systems & Additives, 35 Direct Compression, 34 Controlled & Modified Release, 33 Solubilizers, 33 Thickeners and Stabilizers, 32 Topical, 31 Granulation, 31 Disintegrants & Superdisintegrants, 23 Film Formers & Plasticizers, 22 Parenteral, 21 Lubricants & Glidants, 17 Taste Masking, 16 Co-Processed Excipients, 15 Emulsifying Agents, 9 API Stability Enhancers, 9 Empty Capsules, 8 Chewable & Orodispersible Aids, 7 Surfactant & Foaming Agents, 7 Rheology Modifiers, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 42 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 126 Regulatory FDF Prices, 7 Annual Reports

MARKET PLACE

10 APIs, 3 FDF Dossiers

PATENTS & EXCLUSIVITIES

128 US Patents, 4 US Exclusivities

REF. STANDARDS & IMPURITIES

4 EDQM, 3 USP, 4 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
28/03/2025	Symbiotec Pharmalab	India	Symbiotec Pharmalab Private Limited	22552-0019	Estrogens, Esterified	2010-05-11	2025-12-31	BULK INGREDIENT	POWDER (1g/g)
28/03/2025	Aspen API	Netherlands	Aspen Oss B.V.	60870-0217	ESTROGENS, ESTERIFIED	1977-09-28	2025-12-31	BULK INGREDIENT	POWDER (1g/g)

Estradiol

Estradiol

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

33 API Suppliers

11 USDMF

12 CEP/COS

2 JDMF

3 EU WC

10 KDMF

34 NDC API

4 VMF

17 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

42 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

551 FDF Dossiers

229 FDA Orange Book

222 Europe

29 Canada

34 Australia

27 South Africa

10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.025MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.0375MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.06MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.075MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.1MG/24HR

INSERT, EXTENDED RELEASE;VAGINAL - 0.0075MG/24HR

SYSTEM;TRANSDERMAL - 0.025MG/24HR

SYSTEM;TRANSDERMAL - 0.0375MG/24HR

SYSTEM;TRANSDERMAL - 0.05MG/24HR

SYSTEM;TRANSDERMAL - 0.075MG/24HR

SYSTEM;TRANSDERMAL - 0.1MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.14MG/24HR

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.25MG/24HR

TABLET;ORAL - 0.5MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 1MG;0.5MG

TABLET;VAGINAL - 10MCG

TABLET;VAGINAL - 25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 0.5MG;100MG

CAPSULE;ORAL - 1MG;100MG

GEL, METERED;TRANSDERMAL - 0.06% (1.25GM/ACTIVATION)

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR

TABLET;ORAL - 0.25MG;0.5MG

TABLET;ORAL - 0.5MG;1MG

GEL, METERED;TRANSDERMAL - 0.06% (0.87GM/ACTIVATION)

SPRAY;TRANSDERMAL - 1.53MG/SPRAY

GEL;TRANSDERMAL - 0.1% (0.25GM/PACKET)

GEL;TRANSDERMAL - 0.1% (0.5GM/PACKET)

GEL;TRANSDERMAL - 0.1% (0.75GM/PACKET)

GEL;TRANSDERMAL - 0.1% (1.25GM/PACKET)

GEL;TRANSDERMAL - 0.1% (1GM/PACKET)

CREAM;VAGINAL - 0.01%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Rochem International Inc

8 SPI Pharma

12 DKSH

6 Faran Shimi Pharmaceutical

6 Boai NKY Pharmaceuticals Ltd

5 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 ACG Worldwide

8 Actylis

2 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

33 BASF

1 BioSpectra

1 Clariant

TABLET;ORAL - 0.5MG;0.1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;VAGINAL - 25MCG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons